Data published in British Journal of Cancer validates vascular remodelling of Halaven (eribulin) in breast tumour tissue- Eisai

New data published in the British Journal of Cancer validate the distinct vascular remodelling activity of Halaven (eribulin) from Eisai, compared to bevacizumab in breast tumour tissue. Optical imaging techniques for haemodynamic analysis and blood tests for biomarker analysis show that eribulin increases the oxygen saturation of breast tumour tissue and suppresses TGF-1, a driver of cancer progression associated with poor outcomes for women with advanced breast cancer. This research sheds light on the biology of vascular remodelling and oxygenation response to eribulin.

Contrary to normal cells, cancer cells thrive in a deoxygenated environment. These data show that eribulin is able to increase the density of tiny blood vessels and supply of oxygenated blood to breast cancer tissue. This has the potential to reduce the risk of cancer spreading as the cancer cells can no longer thrive in this environment.